Stay updated on Anetumab Ravtansine Plus Atezolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Anetumab Ravtansine Plus Atezolizumab in NSCLC Clinical Trial page.

Latest updates to the Anetumab Ravtansine Plus Atezolizumab in NSCLC Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoChange DetectedThe page shows a new revision number (v3.5.4) replacing the previous v3.5.3, indicating a minor internal update to the page's documentation.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe page metadata/version label was updated from “Revision: v3.5.2” to “Revision: v3.5.3” without changing the study’s substantive details.SummaryDifference0.1%

- Check39 days agoChange DetectedRevision updated to v3.5.2, replacing the previous v3.5.0.SummaryDifference0.1%

- Check68 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check82 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check104 days agoChange DetectedRevision label updated from v3.4.1 to v3.4.2 on the page.SummaryDifference0.1%

Stay in the know with updates to Anetumab Ravtansine Plus Atezolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Anetumab Ravtansine Plus Atezolizumab in NSCLC Clinical Trial page.